Intrathecal hydrocortisone for treatment of children and young adults with CAR T‐cell immune‐effector cell‐associated neurotoxicity syndrome

How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity

(2023) Bianca D Santomasso et al.   BLOOD

Tumor inflammation-associated neurotoxicity

(2023) Jasia Mahdi et al.   NATURE MEDICINE

Neurotoxicity Following CD19/CD28ζ CAR T-Cells in Children and Young Adults with B-Cell Malignancies

(2022) Haneen Shalabi et al.   NEURO-ONCOLOGY

CD19/22 CAR T-cells in Children and Young Adults with B-ALL: Phase I Results and Development of a Novel Bicistronic CAR

(2022) Haneen Shalabi et al.   BLOOD

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

(2022) Joanna C. Zurko et al.   JAMA Oncology

Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome

(2022) PALASH ASAWA et al.   ANTICANCER RESEARCH

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

(2021) Bianca D. Santomasso et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

(2021) P.J. Hayden et al.   ANNALS OF ONCOLOGY

Intrathecal Chemotherapy: An Alternative Treatment Strategy to Prolonged Corticosteroids for Severe CAR T Associated Neurotoxicity

(2020) Filiz Yucebay et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome

(2020) Nirav N. Shah et al.   Blood Advances

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

(2020) Marcela V Maus et al.   Journal for ImmunoTherapy of Cancer

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE